Abstract
BackgroundTDM-1 was approved in November 2013 by the European Medicines Agency for the treatment of unresectable or metastatic breast cancer in patients who had previously received Trastuzumab and a taxane...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
